Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expec ...
Scotiabank lowered the firm’s price target on Kura Oncology (KURA) to $10 from $18 and keeps a Sector Perform rating on the shares. The firm ...
Scotiabank lowered the firm’s price target on Syndax (SNDX) to $16 from $18 and keeps a Sector Perform rating on the shares. The firm adjusted ...
BioSkryb launches ResolveSEQ MRD, an innovative service offering designed to empower further classification and characterization of MRD cells.
Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expec ...
A British mum has revealed how having puffy eyes ended up being a symptom of a rare form of cancer. Lizzie Spear, 56, had ...
CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were ...
Little Aria Stevenson’s smiles are thanks to the kindness of strangers whose blood donations have helped her through ...
In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback